Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
Zymeworks (Nasdaq: ZYME), a clinical-stage biotechnology company focused on developing novel biotherapeutics for cancer, inflammation, and autoimmune diseases, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after market close on May 8, 2025, followed by a conference call and webcast at 4:30 pm Eastern Time on the same day. Management will provide both financial updates and a corporate overview during the call.
Zymeworks (Nasdaq: ZYME), un'azienda biotecnologica in fase clinica specializzata nello sviluppo di nuovi bioterapeutici per il cancro, l'infiammazione e le malattie autoimmuni, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025. La società pubblicherà i risultati del Q1 2025 dopo la chiusura del mercato l'8 maggio 2025, seguiti da una conference call e webcast alle 16:30 ora Eastern dello stesso giorno. Il management fornirà aggiornamenti finanziari e una panoramica aziendale durante la chiamata.
Zymeworks (Nasdaq: ZYME), una empresa biotecnológica en etapa clínica enfocada en desarrollar nuevos bioterapéuticos para el cáncer, la inflamación y enfermedades autoinmunes, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025. La compañía publicará sus resultados del Q1 2025 después del cierre del mercado el 8 de mayo de 2025, seguido de una llamada conferencia y webcast a las 4:30 pm hora del Este el mismo día. La dirección ofrecerá actualizaciones financieras y una visión general corporativa durante la llamada.
Zymeworks (나스닥: ZYME)는 암, 염증 및 자가면역 질환을 위한 새로운 생물치료제 개발에 주력하는 임상 단계의 생명공학 회사로, 2025년 1분기 재무 실적 발표 일정을 잡았습니다. 회사는 2025년 5월 8일 장 마감 후 1분기 2025 실적을 발표하며, 같은 날 동부 표준시 오후 4시 30분에 컨퍼런스 콜과 웹캐스트가 진행됩니다. 경영진은 통화 중 재무 업데이트와 회사 개요를 제공할 예정입니다.
Zymeworks (Nasdaq : ZYME), une entreprise biotechnologique en phase clinique spécialisée dans le développement de nouveaux biothérapeutiques pour le cancer, l'inflammation et les maladies auto-immunes, a programmé l'annonce de ses résultats financiers du premier trimestre 2025. La société publiera ses résultats du T1 2025 après la clôture des marchés le 8 mai 2025, suivis d'une conférence téléphonique et d'un webcast à 16h30, heure de l'Est, le même jour. La direction fournira des mises à jour financières ainsi qu'un aperçu de l'entreprise lors de l'appel.
Zymeworks (Nasdaq: ZYME), ein biotechnologisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuartiger Biotherapeutika für Krebs, Entzündungen und Autoimmunerkrankungen spezialisiert hat, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 geplant. Das Unternehmen wird seine Q1 2025-Ergebnisse nach Börsenschluss am 8. Mai 2025 veröffentlichen, gefolgt von einer Telefonkonferenz und einem Webcast um 16:30 Uhr Eastern Time am selben Tag. Das Management wird während des Anrufs finanzielle Updates und einen Unternehmensüberblick geben.
- None.
- None.
VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its first quarter 2025 financial results after market close on May 8, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 8, 2025 at 4:30 pm Eastern Time.
The event will be webcast live with dial-in details and webcast replays available on Zymeworks’ website at https://ir.zymeworks.com/events-and-presentations.
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz Pharmaceuticals), granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) second-line biliary tract cancer (BTC). Ziihera® is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. Zanidatamab is currently under regulatory review in the EU and China for second-line BTC and is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with an investigational new drug application for ZW251 planned for mid-2025. In addition to Zymeworks’ pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
FAQ
When will Zymeworks (ZYME) release its Q1 2025 earnings?
How can investors access Zymeworks' Q1 2025 earnings call?
What therapeutic areas does Zymeworks (ZYME) focus on?
What type of company is Zymeworks (ZYME)?
